Ongoing phase 3 trials are in progress, and CagriSema is currently under FDA review, with a decision expected in late 2026
This system helps protect the peptide as it moves through the digestive tract, allowing for improved absorption through the oral and intestinal lining
Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, et al
Human clinical studies by Schneider-Helmert and Schoenenberger (1986) demonstrated that DSIP administration improved sleep quality in chronic insomniacs, with particular improvement in sleep onset latency and delta sleep duration
Biochemical and Structural Studies of 6-Carboxy-5,6,7,8-Tetrahydropterin Synthase Reveal the Molecular Basis of Catalytic Promiscuity within the Tunnel-Fold Superfamily